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The use of preimplantation genetic testing for aneuploidies is highly debated. This theoretical study 
suggests that the procedure can be economically advantageous when employed in specific settings 





Objective: To evaluate the economical benefit of preimplantation genetic testing of aneuploidies 
(PGT-A) when applied in an extended culture and stringent elective Single Embryo Transfer 
(eSET) framework.   
Design: Theoretical cost-effectiveness study  
Setting: Center with established expertise in trophectoderm biopsy for preimplantation genetic 
testing of monogenic disorders. 
Patients/Animals: None  
Intervention: Comparison of the cost-effectiveness between two IVF treatment strategies: i) serial 
transfer of all available blastocysts without genetic testing (first fresh transfer and subsequent 
frozen-thawed transfer) and ii) systematic use of genetic testing (trophectoderm biopsy, freeze all 
and frozen-thawed transfers of euploid blastocysts). The costs considered for this analysis are based 
on regional public health system provider. 
Main Outcome Measure: Costs per live birth 
Results: Cost-effectiveness profile of PGT-A improves with female age and number of available 
blastocysts. Sensitivity analyses varying the costs of embryo transfer, the costs of genetic analyses, 
the magnitude of the detrimental impact of PGT-A on live birth rate and the crude live birth rates 
change to some extent the thresholds for effectiveness but generally confirm the notion that PGT-A 
can be economically advantageous in some specific subgroups. 
Conclusions: PGT-A can be cost-effective in specific clinical settings and population groups. 
Economical considerations deserve attention in the debate regarding the clinical utility of PGT-A. 
 






Since its first success in 1978, in vitro fertilization (IVF) has undergone enormous improvements 
and subsequent widespread application (1). Some of the most recent achievements in the field 
include prevention of Ovarian Hyperstimulation Syndrome (OHSS) (2) and the drastic reduction of 
multiple pregnancy through extensive adoption of elective single embryo transfer (eSET) strategy 
(3). This latter approach has been facilitated by the implementation of extended embryo culture (up 
to the blastocyst stage), allowing the selection of embryos with higher reproductive potential.   
In a similar way, preimplantation genetic testing of aneuploidies (PGT-A), a methodology that 
allows comprehensive testing of embryonic cells chromosomal complement, strives to de-select 
aneuploid embryos and could prove an important step forward for improving the effectiveness of 
eSET. However, the utility of this technology is currently debated (4-9). On one hand, PGT-A 
improves embryo selection (10) and is more patient friendly (women have to undergo fewer embryo 
transfers and face a lower risk of miscarriage) (11). On the other hand, this approach increases the 
costs of the procedure and could lead to the erroneous discarding of healthy embryos, thus reducing 
the cumulative chances of live birth per oocytes retrieval. Indeed, although rare, PGT-A can provide 
false positive results (12) and the biopsy of the trophectoderm cells may impact embryo’s viability, 
hence its implantation potential, particularly if the procedure is not performed properly (13). 
Surprisingly, the burning debate on the role of PGT-A has given limited attention to cost-
effectiveness considerations (14,15). This is in contrast with the current strong global commitment 
for equity and sustainability (16). Optimized cost-effectiveness of treatments is a main priority in 
modern medicine. A relevant point in destabilizing the equilibrium of this debate is the continuous 
decrease in diagnostic costs since the adoption of Next Generation Sequencing (NGS) platforms for 
PGT-A. Despite inevitably increasing procedural complexity and IVF costs, PGT-A can still result 
in higher cost-effectiveness when applied in specific clinical contexts.  
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Current strategies for the management of infertile women undergoing IVF vary broadly and are 
influenced by national legislations and regulations, cultural environments, payment modalities 
(public funded, insurance based or pure private) and local expertise and equipment. As a 
consequence, performing cost-effectiveness analyses with the purpose of drawing conclusions that 
could be valid worldwide is unrealistic. For this reason and with the aim of providing an unbiased 
assessment study on the potential economical benefit of PGT-A, we focused our proof of concept 
study on a highly specialized clinical setting (a referral Center with established expertise on 
trophectoderm biopsy and a stringent policy of eSET) and treating a highly selected population 
(patients retrieving a sufficient number of good quality oocytes to allow the extended culture 
strategy). Specifically, we compared the cost-effectiveness profile of two strategies: i) serial transfer 
of all available blastocysts without genetic testing (first fresh transfer and subsequent frozen-thawed 
transfers) and ii) systematic use of genetic testing (trophectoderm biopsy, freeze all and frozen-
thawed transfers of euploid blastocysts). The analyses were performed varying the female age and 
the number of available blastocysts.  
 
 
Materials and methods 
 
This study evaluated economical differences a conventional approach without genetic testing and an 
approach with the systematic use of PGT-A. The two strategies are outlined in Figure 1. The 
primary aim of the study was to identify thresholds for female age and number of available 
blastocysts that determines a high cost-effectiveness of PGT-A compared to the conventional 
approach.  The study was based on a theoretical model and was thus exempted from acceptance of 
Institutional Review Board. 
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The model applies to women who have viable blastocysts (n ≥ 1) for transfer in the context of a 
rigid and systematic policy of eSET policy. In order to generalize the results of the analysis, we 
considered a scenario where the health provider covered all procedures charges and costs, thus 
excluding more complex and financially heterogeneous schemes (i.e. insurances). The assumptions 
made for developing the model are reported in details in Supplemental Table 1. The most relevant 
ones were the following: 1) PGT-A is associated with a 5% relative reduction in live birth rate due 
to the theoretical biopsy-related damage to the embryo and to the false positive results that may 
derive from the inherent technical error of chromosomal diagnostics (12,17-20). In fact, there are no 
definitive and precise estimates for this rate. Nonetheless, a conservative 5% rate was assumed 
despite recent evidence demonstrating no major effect of the biopsy on embryo viability (12) and 
indicating a false positive rate lower than 5% (17;19;20); 2) miscarriage rate following PGT-A is 
constant at 8% per eSET regardless of female age (21), 3) local technical expertise and 
trophectoderm biopsy equipment is in place (i.e. an active program for preimplantation genetic 
testing for monogenic disorders was assumed), 4) although the proportion of pregnant women 
undergoing first trimester testing for aneuploidy identification (i.e., amniocentesis) may be lower in 
the PGT-A group, this variable was excluded due to lack of scientific data.  
Costs involved in the two alternative models are summarized in Supplemental Table 2. When 
available, final charges rather than pure costs were included. Specifically, most 
treatment/procedures costs were retrieved from the local Diagnosis-Related Group (DRG) 
reimbursements (http://www.e-drg.it/drg24/Codici.htm) whilst costs of the drugs were obtained 
from the local medical agency (AIFA: Agenzia Italiana del Farmaco, 
http://www.agenziafarmaco.gov.it). However, the local DRGs for IVF did not include PGT-A. For 
this reason, specific costs for PGT-A were calculated independently and added to the DRG. They 
included costs associated to freezing surplus embryos, embryo biopsies and genetic analyses. 
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Pregnancy supplements were considered independent costs because they were not part of the DRG-
related reimbursement for IVF.  
The formulae used to calculate the costs of the two strategies were as follows: 
Conventional approach 
TotKConv =  (N.Blasto * KET)  +  (PmiscConv * Kmisc) 
+  [(PmiscConv + LBRConv) * KdrugsPreg] 
-   [If N.Blasto >1, (N.Blasto / 2) * LBRConv * KET]  
PGT-A approach  
TotKPGTA = KPGTA  +  [Peuploidy * N.Blasto * KET)  +  (PmiscPGTA * Kmisc) 
  +  [(PmiscPGTA + LBRPGTA) * KdrugsPreg] 
-   [If N.Blasto >1, (Peuploidy *N.Blasto / 2) * LBRPGTA * KET] 
K is used for costs. Specifically: “TotKConv” stands for total costs of the conventional approach / 
“TotKPGTA” stands for total costs of the PGT-A approach / “KET” stands for costs of fresh or frozen 
embryo transfer / “KPGTA” stands for costs of the PGT-A (that varies with the number of available 
blastocysts) / “Kmisc” stands for costs of miscarriage management / “KdrugsPregnant” stands for drug 
costs for supplementation when pregnancy starts. The letter P is used for probability. Specifically: 
“PmiscConv”  and “PmiscPGTA”  stand for the absolute rates of miscarriage in the conventional and PGT-
A approaches, respectively / Peuploidy indicates the probability of euploidy. LBRConv and LBRPGTA 
are also probabilities as they indicate the Live Birth Rate in the conventional and PGT-A groups, 
respectively. As shown in the two formulae, there is a subtraction (only for women with > 1 
blastocyst) because we assumed that, in women achieving pregnancy, only half of the blastocysts 
had to be transferred.  
The chances of pregnancy and live birth were obtained from the ART Italian Register 
(http://old.iss.it/rpma). Since data was not presented per year but per age group, a linear regression 
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was performed to calculate the live birth and miscarriage rates for every single age category. 
Specifically, the following regression curves were used for these calculations: 
 Cumulative Live birth rate per retrieval: Y = (- 0.022 * X) + 1.036   (X is age) 
 Miscarriage rate: Y = (0.024 * X) – 0.584   (X is age) 
Similarly, to obtain homogeneous data on the risk of aneuploidy, we used a database of PGT-A 
results including >10,000 cases kindly provided by Igenomix and performed a regression curve to 
produce standardized rates. The regression curve was as follows: 
 Euploide rate:  Y = (-0.057 * X) + 2.669   (X is age) 
The clinical pregnancy rates, live birth rates, miscarriage rates and aneuploidy rates estimated using 
these calculations are shown in Supplemental Table 3. 
The data are presented as cost-effectiveness ratios between the cost per live birth for the PGT-A 
strategy and the cost per live birth for the conventional approach. Ratios > 1 indicate that PGT-A is 
more cost-effective while ratios < 1 indicate that the conventional approach is more cost-effective.  
Primary sensitivity analyses were done for age and number of available blastocysts. Specifically, 
age was moved over an 11 points axis, starting with the group of women aged ≤34 years of age and 
then providing point estimates for every year up to age 44. Precise year estimates for women under 
35 were not provided because the chances of pregnancy, miscarriage and aneuploidy do not vary 
significantly across this population. Moreover, the model was discontinued after age 44 because 
pregnancies ≥45 years are exceptional events. The maximum number of blastocysts was 4 because 
trends were clear. The inclusion of analyses for younger women and cases with  ≥ 5 blastocysts 
would not have brought additional meaningful insights, though complicating the presentation of the 
results. Additional sensitivity analyses were performed by halving the costs of the embryo transfer 
procedures (from € 2194 to € 1097), increasing the detrimental impact of the PGT-A on the live 
birth rate (from 5% to 10-15%), modifying the costs of PGT-A (from +25% to -25%) and varying 
the live birth rates (applying a relative increase and decrease of 25%). The decision of applying a 
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higher variability for the charges of the embryo transfer procedure (-50%) was based on a recent 
local debate on the magnitude of the DRG-related reimbursement (some stakeholders estimate € 
2,194 to excessive). Drug costs were not included since they are expected to be similar for the two 
strategies.  
Calculations were performed using Microsoft Excel. For readers interested in replicating the 
analyses by adapting individual costs to their contexts, this file is available as an additional material 
(appendix) for those interested in replicating the analyses in different contexts by adapting the items 
of costs. In addition to the results presented in the paper, the file includes analyses up to 6 





Cost-effectiveness ratios between the two strategies calculated per age and number of available 
blastocysts are shown in Figure 2 (upper panel). In general, the PGT-A strategy becomes more 
cost-effective with an increase of age. Specifically, it is superior to the conventional approach for 
women aged ≥36 years and for those aged 35 with at least three blastocysts. Taking into account the 
aforementioned ongoing discussion among stakeholders surrounding the magnitude of the local 
reimbursement for the fresh or frozen embryo transfer procedures, we also performed sensitivity 
analysis considering half of the currently reimbursed cost (e.g. reducing it from € 2,194 and € 1,097 
(Figure 2, lower panel). In this scenario, the threshold ages favoring the PGT-A strategy are 42, 40, 
39 and 38 years for one, two, three and four blastocysts, respectively. 
Sensitivity analyses modulating the detrimental impact of PGT-A on live birth rate, the costs of 
genetic analyses and the live birth rate are presented in Table 1. Data is presented separately for the 






In this study, we showed that, in a referral center for preimplantation detection of monogenic 
diseases performing extended embryo culture and eSET, the PGT-A approach could be cost-
effective. In our specific economical setting, the procedure is actually not advantageous up to at 
least age 35-36. Afterwards, PGT-A overcomes the conventional approach at different age 
thresholds depending on the number of available blastocysts. When halving the costs of embryo 
transfer (as this might better reflects general worldwide contexts), the PGT-A remains financially 
advantageous, although it becomes more cost-effective at older ages (38-42 years according to the 
number of available blastocysts). Moreover, the sensitivity analyses showed that the model is 
minimally influenced by the live birth rates and by the magnitude of the theoretical detrimental 
impact of the PGT-A strategy on the cumulative chances of pregnancy. Conversely, the costs of the 
PGT-A may be more relevant. More prominent differences emerged when varying these costs from 
+25% to -25%. The context of a 25% reduction of PGT-A costs deserves attention considering that 
analytical costs may continue to reduce in the near future.  
Hot topics fuelling current debate on PGT-A include additional costs of the genetic analyses, 
possible biopsy-related injury to the blastocysts, potential psychological benefits of preventing 
miscarriages, possible increased iatrogenic rate of aneuploidy due to an excessive ovarian hyper-
stimulation, effects of blastocysts versus cleavage stage transfers and inherent biological errors in 
chromosomal diagnosis (4-9). In this study, we aimed to provide an evaluation from a different 
viewpoint that has been often disregarded: the evaluation of PGT-A from a mere cost-effectiveness 
perspective. With this purpose, we focused on a particular setting and we tried to take balanced 
assumptions that could be acceptable for both those in favor and against the use of PGT-A. For the 
most debated arguments, we decided to favor the conventional approach for precautionary reasons 
as prudence is always preferred when discussing the possible adoption of a new expensive approach 
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in clinical practice. For instance, we have included in the calculations an overall reduction in live 
birth rates due to possible biopsy-associated embryonic damage or the incomplete accuracy of the 
genetic analysis (5% in the baseline scenario, increased to 10-15% in the sensitivity analyses). 
However, we did not consider the potential beneficial effects of PGT-A on the drop-out rates and 
we assumed that the frequency of prenatal genetic investigations would be similar in the two 
groups.  
The two previously published economical studies on PGT-A reported contrasting results. Indeed, 
Collins et al. focused on women older than 37 years and concluded that the PGT-A strategy could 
be more cost-effective (14). However, this study did not focus on eSET and did not take into 
consideration the potential additional benefits of transferring supernumerary frozen blastocysts, thus 
providing only a partial evaluation of the two approaches. Moreover, no attempts to identify 
effectiveness thresholds for age and number of blastocysts were made. Scriven investigated the 
cost-effectiveness profile of PGT-A using a complex and intricate model and failed to show any 
benefit (15). However, the virtual population tested was young (median age of 33, range 22-39) and 
no strata analyses were performed. This is a crucial point because, as shown in our model, the age 
of the women is fundamental and the negative conclusions emerging from this study cannot be 
inferred to the whole population of women undergoing IVF. 
Some limitations of our study should be recognized. Firstly, the study is based on a theoretical 
model rather than on a RCT. On the other hand, it has to be considered that an exceptionally large 
and possibly unachievable RCT would be required to provide a reliable answer to the specific query 
of our study (e.g. from which thresholds of age and number of blastocysts a strategy of PGT-A 
becomes more cost-effective). In fact, some of the assumptions listed in Supplemental Table 1 lack 
robust scientific support and may be questioned (in particular points N. 2, 3, 5, 12, 13, 14 and 15). 
Some of these uncertainties were addressed with the sensitivity analyses (N. 2 and 3). Notably, 
although the statement that the number of available blastocysts does not influence the chance of 
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success (point N. 3) is obviously debatable, the sensitivity analysis highlighted the limited relevance 
of this approximation: the model was not influenced by modifying the chances of pregnancy (Table 
1). Other assumptions were also estimated (as available evidence is yet insufficient) but were 
generally conservative. They included a similar rate of obstetrics complications (point N. 12) across 
strategy groups, a similar attendance to first trimester screenings (point N. 13), the irrelevance of 
miscarriage on quality of life (point N. 14) and a similar rate of drop-out (point N. 15). All these 
assumptions were actually expected to partly favor the conventional approach, thus protecting our 
conclusions from criticism.   
Secondly, we started from a very specific scenario. The specific thresholds for cost-effectiveness 
emerging from our study may actually be valid only for a situation similar to the one described (e.g. 
high biopsy competence, extended embryo culture and extensive eSET application). Inferences to 
other settings could not be extrapolated and thresholds should be recalculated based on local 
conditions. Moreover, one could argue against the policy of stringent and systematic eSET 
regardless of age. The scenario can indeed significantly change if more than one blastocyst is 
transferred. Specific cost-effectiveness analyses (including the additional costs of twin pregnancies) 
would be required to address this issue. These analyses are however beyond the scope of the present 
study which strictly adheres to the modern plea for a drastic prevention of multiple pregnancies. 
Finally, we did not include time to pregnancy analyses in our model. Such analysis may ultimately 
favor PGT-A, in particular for older women with several blastocysts. Indeed, PGT-A could be 
expected to reduce the rate of patients’ drop-out since the burden of treatment is lowered (less 
transfers to perform) and may shorten time to pregnancy. This issue was not addressed because 
reliable real-life data on the impact of PGT-A on the rate of drop-out is not available. 
Thirdly, the use of the local health provider perspective partly limits the generalization of our 
findings. Of relevance here is the elevated reimbursement associated to the embryo transfer 
procedure (€ 2,194 for either fresh and frozen embryo transfer), a decision that was presumably 
14 
 
taken by stakeholders to indirectly favor eSET in order to shrink multiple pregnancies (no specific 
legislation on the number of embryos to be transferred exists in Italy). It should be noted that our 
analyses were mainly based on charges rather than pure costs. We evaluated pure costs only for the 
few items that are not currently considered by the local health provider. To prevent criticisms on the 
generalization of our findings, we thus decided to perform a primary sensitivity analysis that halved 
the charges for embryo transfer. Moreover, we performed other secondary sensitivity analyses 
varying the most relevant items. All these analyses generally support the conclusion that PGT-A 
could be cost-effective in the different scenarios. Nonetheless, we believe that evaluations using 
local data should be performed to recommend stringent thresholds for the use of PGT-A in clinical 
practice. To facilitate this objective, we have included in the supplementary material the Excel 
matrix used to elaborate the cost-effectiveness model for the present study (see Appendix in the 
Supplementary material). This template can assist the readers in developing their own cost-
effectiveness models based on internal data and specific costs and socio-economical settings. 
Finally, it is interesting to note that the model is not sensitive to patient’s prognosis: varying live 
birth rates from -25% to +25% did not show any impact on the analysis outcome. As a 
consequence, one may infer that cost-effectiveness of PGT-A may not be influenced by specific 
diagnostic or prognostic subgroups. 
In conclusion, cost-effectiveness analyses deserve utmost consideration in the debate on the clinical 
utility of PGT-A. Our study shows that the PGT-A can be cost-effective after age 35 in referral 
centers with expertise in trophectoderm biopsy and that follow a policy of extended embryo culture 
and stringent eSET. However, we could not infer universal thresholds of age and number of 
blastocysts for recommending PGT-A as these thresholds can vary depending on local clinical 
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Figure 1: Strategies for the clinical management of women with viable blastocysts. The 
conventional approach (serial transfer of all the available blastocysts) is shown in the left side. The 
approach with systematic preimplantation genetic testing for aneuploidie (PGT-A) is shown in the 
right side. In PGT-A strategy, fresh embryo transfer is never performed and the total number of 
transfers is lower (aneuploid blastocysts are discarded).  
 
Figure 2: Costs ratios between PGT-A and conventional approaches according to age and 
number of available blastocysts. Ratios > 1 indicate that PGT-A is more cost-effective while ratios 
< 1 indicate that the conventional approach is more cost-effective. The original model is shown in 
the upper panel. The lower panel shows results when a 50% reduction in the cost of the embryo 
transfer procedure was applied.  
 
